Sol-Gel enters 6 license agreements to commercialize TWYNEO, EPSOLAY

Sol-Gel Technologies announced it has entered into six exclusive license agreements with MagnaPharm Trading Slovakia S.R.L, Galenica A.B, Leman SKL SA, InfectoPharm, Aspire Pharma Limited and Abex Pharmaceutica for the commercialization of TWYNEO and EPOSLAY covering the majority of the European countries, including Germany, United Kingdom, France, Poland, Romania, Greece, Czech Republic, Sweden, Hungary, Austria, Switzerland, Serbia, Bulgaria, Finland, Slovakia, Norway, Croatia, Bosnia and Herzegovina, Albania, Lithuania, North Macedonia, Slovenia, Latvia, Estonia, Iceland, and South Africa. Under the terms of the agreements, Sol-Gel is to receive upfront and regulatory milestones payments totaling in up to low 7-digit USD as well as either future fixed transfer price or future low double digit royalties from net sales payments which are backed by commitments to minimum annual sales. The regulatory submissions in the various territories are the responsibility of Sol-Gel’s partners, and Sol-Gel will assist its partners in preparing these submissions.